Efficacy of recombinant sialoglycoprotease in protection of cattle against pneumonic challenge with Mannheimia (Pasteurella) haemolytica A1

Shewen, Patricia E.; Lee, Chiang W.; Perets, Ann; Hodgins, Douglas C.; Baldwin, Katherine; Lo, Reggie Y.C.

doi:10.1016/s0264-410x(03)00002-1

Cited by 20 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…M. haemolytica vaccines have traditionally been tested using one to two doses of vaccine with intratracheal, intrabronchial, or transthoracic challenge approximately 14 days after the last vaccination (12,39). Clinical signs are usually evaluated and cattle are euthanized and necropsied 4 to 6 days after challenge, with lung lesions quantified and compared to lesions in nonvaccinates.…”

Section: Discussionmentioning

confidence: 99%

Proteomic Analysis and Immunogenicity of Mannheimia haemolytica Vesicles

Ayalew

Confer

Shrestha

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

b Mannheimia haemolytica, a major causative agent in bovine respiratory disease, inflicts extensive losses each year on cattle producers. Commercially available vaccines are only partially efficacious. Immunity to M. haemolytica requires antibodies to secreted toxins and outer membrane proteins (OMPs) of the bacterium. Gram-negative bacteria produce membrane blebs or vesicles, the membrane components of which are primarily derived from OMPs. Accordingly, vesicles have been used as immunogens with various degrees of success. This study characterized components of M. haemolytica vesicles and determined their immunogenicity in mice and cattle. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of vesicles from this bacterium identified 226 proteins, of which 58 (25.6%) were OMPs and periplasmic and one (0.44%) was extracellular. Vesicles were used to vaccinate dairy calves and BALB/c mice. Analyses of sera from calves and mice by enzyme-linked immunosorbent assay (ELISA) showed that circulating antibodies against M. haemolytica whole cells and leukotoxin were significantly higher on days 21 and 28 (P < 0.05) than on day 0. For control calves and mice, there were no significant differences in serum anti-whole-cell and leukotoxin antibody levels from days 0 and 21 or 28, respectively. Lesion scores of lungs from vaccinated calves (15.95%) were significantly (P < 0.05) lower than those from nonvaccinated calves (42.65%). Sera from mice on day 28 and calves on day 21 showed 100% serum bactericidal activity. Sera from vesicle-vaccinated mice neutralized leukotoxin.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic Analysis and Immunogenicity of Mannheimia haemolytica Vesicles

Ayalew

Confer

Shrestha

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…These include live M. haemolytica (2,6,7,9,11,19,21,33,50), killed M. haemolytica cells (10,20,22,23,52), components or fractions of M. haemolytica cells (17,24,27,28,35,49,(53)(54)(55), and commercial vaccines (57,58). While immunity to M. haemolytica appears to require anti-LKT and antisurface antigen antibodies (55), partial protection could be afforded to cattle experimentally vaccinated with M. haemolytica preparations that did not contain LKT (21,40).…”

Section: Discussionmentioning

confidence: 99%

Characterization of Immunodominant and Potentially Protective Epitopes of Mannheimia haemolytica Serotype 1 Outer Membrane Lipoprotein PlpE

2004

View full text Add to dashboard Cite

Mannheimia haemolytica serotype 1 (S1) is the most common bacterial isolate found in shipping fever pneumonia in beef cattle. Currently used vaccines against M. haemolytica do not provide complete protection against the disease. Research with M. haemolytica outer membrane proteins (OMPs) has shown that antibodies to one particular OMP from S1, PlpE, may be important in immunity. In a recently published work, members of our laboratory showed that recombinant PlpE (rPlpE) is highly immunogenic when injected subcutaneously into cattle and that the acquired immunity markedly enhanced resistance to experimental challenge (A. W. Confer, S. Ayalew, R. J. Panciera, M. Montelongo, L. C. Whitworth, and J. D. Hammer, Vaccine 21:2821-2829, 2003). The objective of this work was to identify epitopes of PlpE that are responsible for inducing the immune response. Western blot analysis of a series of rPlpE with nested deletions on both termini with bovine anti-PlpE hyperimmune sera showed that the immunodominant region is located close to the N terminus of PlpE. Fine epitope mapping, in which an array of overlapping 13-mer synthetic peptides attached to a derivatized cellulose membrane was probed with various affinity-purified anti-PlpE antibodies, identified eight highly reactive regions, of which region 2 (R2) was identified as the specific epitope. The R2 region is comprised of eight imperfect repeats of a hexapeptide (QAQNAP) and is located between residues 26 and 76. Complementmediated bactericidal activity of affinity-purified anti-PlpE bovine antibodies confirmed that antibodies directed against the R2 region are effective in killing M. haemolytica.Bovine respiratory disease arises from the interaction of numerous contributing factors, including physical stresses associated with weaning, shipment, inclement weather, and overcrowding coupled with viral and bacterial infections (8,31,32,59,63). The result in severe cases is colonization of the lungs with pathogenic bacteria resulting in severe pneumonia. Pasteurella multocida, Haemophilus somnus, and Mannheimia (formerly Pasteurella) haemolytica are associated with bovine pneumonia. However, M. haemolytica serotype 1 (S1) is by far the most important bacterial pathogen in the development of the often-fatal fibrinous pleuropneumonia in beef cattle known as pneumonic pasteurellosis or shipping fever (31, 32).Immunity against M. haemolytica is thought to be primarily through production of serum antibodies that neutralize the secreted leukotoxin (LKT) and antibodies against surface antigens (45). The mechanism of activity of antisurface antibodies and the specific surface antigens involved in anti-M. haemolytica immunity are not known; however, complementmediated bacterial lysis and bacterial phagocytosis and killing are thought to be important in defense against M. haemolytica infection (45). Complement-mediated bactericidal activity against M. haemolytica and phagocytosis of M. haemolytica by bovine neutrophils has been demonstrated with bovine immune serum (12,17,40,46).Litt...

show abstract

“…[23][24][25][26][27] In addition, three terminal studies (five trials) investigated the use of commercially available vaccines in feedlot cattle with a pathogen-challenged disease model [14,28,29], three studies (five trials) utilized dairy or beef calves with naturally occurring disease to investigate effects of vaccination [27,30,31], and thirteen studies investigated the use of commercially available vaccines in dairy calves with an induced-disease model. [32][33][34][35][36][37][38][39][40][41][42][43][44] Studies were excluded from the review: if they did not report original data (primary study), if they did not include a non-vaccinated/placebo control group, if the outcome did not include an assessment of morbidity risk, mortality risk, or extent of lung involvement (e.g. only reported serologic titers), or if the same results were published in a more complete form elsewhere.…”

Section: Methodsmentioning

confidence: 99%